Default company panoramic image
Logo

Nanovega

Diagnosis of cancer with unsurpassed sensitivity and specificity using patented, synthetic antibodies.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded May 2006
  • Employees 3
  • Website nanovega.com

Company Summary

Nanovega specializes in cancer diagnosis: BioTags™ target cell surface receptors and intracellular domains with exceptional specificity and sensitivity. OncoTags™ target cancer cells specifically, tag them permanently and omit healthy cells entirely. These technologies empower researchers and clinicians with the unsurpassed ability to diagnose cancer cells at early stages, which are otherwise not detectable by any other technology in the world.

Team

  • Default avatar
    Marek Malecki MD PhD
    President

    MD, Molecular Medicine (w/Prof. A. Horst)
    Fellowship Rigshospitalet (w/Prof. F. Buchthal)
    PhD, Molecular Biology (w/Prof. L. Lubinska)
    Editor-In-Chief for: Stem Cell Research & Therapy; Genetic Syndromes & Gene Therapy
    Inventor on 8 patents
    Invited speaker at professional conferences
    Director and faculty at the professional courses
    First author on the high impact peer-reviewed articles in the professional journals
    Currently Visiting P

Advisors

  • Default avatar
    Michael Wise & Lara Dueppen
    Lawyer
    Unconfirmed
    Default avatar
    Perkins & Coie
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Founder
    Unconfirmed